Navigation Links
Artemis Diagnostics awarded two grants from Technology Strategy Board to develop cancer imaging technology
Date:12/7/2012

HERTFORDSHIRE, United Kingdom, Dec. 7, 2012 /PRNewswire-iReach/ -- Artemis Diagnostics, a developer of innovative imaging technologies for cancer surgery, announced today that the company has been awarded two Smart grants from the Technology Strategy Board, the UK's innovation agency. The two grants, totaling more than £120,000 (US$ 193,000), provide funding for the company to develop its imaging devices for clinical trials and to undertake market research in the US and UK.

Dr David Tuch, CEO of Artemis Diagnostics, commented, "We are pleased the Technology Strategy Board has selected Artemis Diagnostics to receive funding for our product development and market research. The Smart scheme is highly competitive and these awards provide further affirmation of the company's technology and the tremendous need for improved tools to detect cancer during surgery. We believe our molecular imaging technology will provide a significant advance in precision-guided surgery. We look forward to working with our surgeon collaborators to bring our technology into clinical trials."

About the Technology Strategy Board
The Technology Strategy Board is the UK's innovation agency.  Its goal is to accelerate economic growth by stimulating and supporting business-led innovation.  Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit www.innovateuk.org.

About the Smart scheme
Managed by the Technology Strategy Board, the Smart scheme offers funding to small and medium-sized enterprises (SMEs) to engage in R&D projects in the strategically important areas of science, engineering and technology
'/>"/>

SOURCE Artemis Diagnostics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Global Market for Molecular Diagnostics to Exceed $10.7 Billion by 2018, Regenerative Medicine to Top $4.4 Billion
2. High Degree of Disease Prevalence Sustains Diabetes Diagnostics Market in Europe, Finds Frost & Sullivan
3. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
4. Cynosure to Present at Canaccord Genuity Medical Technology & Diagnostics Forum
5. Biomarkers in Drug Discovery - Integration in Early Stage Promotes Use of Companion Diagnostics to Optimize Therapeutic Outcomes
6. Roche Diagnostics Breaks Ground on New Learning and Development Center
7. Mayor Greg Ballard to Join Roche Diagnostics Leaders at Groundbreaking of New Learning and Development Center
8. Quest Diagnostics Confirms Investor Day on November 16
9. Johnson & Johnson Postpones Medical Devices & Diagnostics Review
10. Johnson & Johnson to Host Medical Devices & Diagnostics Review
11. Life Technologies to Partner with Bristol-Myers Squibb for Companion Diagnostics Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... A new Manhattan Research study, ... finds that members of pharmacy and therapeutics ... and pharmacy benefits managers (PBMs) are shifting the ... of formulary decision makers report that they are ... decision making process today than a year ago. ...
(Date:7/14/2014)...  Clinicians at a leading cancer center in ... first in the country to commence advanced lung, ... Clinac® medical linear accelerator from Varian Medical Systems ... High Intensity Mode dose delivery capability, which is ... treatment times and deliver stereotactic body radiotherapy and ...
(Date:7/14/2014)... 14, 2014  Patients and patient advocates are rallying ... and other major pharmacy benefit managers (PBMs) begin unprecedented ... impact millions of patients who rely on compounded medicines ... pain from cancer, diabetes and other illnesses. Express Scripts ... on July 15. In a matter of ...
Breaking Medicine Technology:Digital Resources Play Critical Role in Formulary Decision Making 2Digital Resources Play Critical Role in Formulary Decision Making 3Yashoda Cancer Institute Commences Radiosurgery Treatments Using Varian Clinac Linear Accelerator 2Yashoda Cancer Institute Commences Radiosurgery Treatments Using Varian Clinac Linear Accelerator 3Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 2Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 3Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 4
... SOUTHAMPTON, England, June 29 Vantia ... drugs,targeting large, underserved medical markets, announces positive results ... development compound VA106483 for,nocturia. The trial showed that ... sustained anti-diuretic effect in patients, as determined by,increased ...
... England and TOKYO, June 29 , ... Sosei Group Corporation ("Sosei"; TSE Mothers ... commencement of a Phase III,clinical study by Novartis, with NVA237, ... obstructive pulmonary disease,(COPD). NVA237 is a dry powder formulation for ...
Cached Medicine Technology:Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 2Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 2Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4
(Date:7/14/2014)... July 14, 2014 The North America ... in North America with analysis and forecast of revenue. ... grow from around $273.1 million in 2013 to $490.1 ... 2013 to 2018. , Browse through the TOC of ... idea of the in-depth analysis provided. This also provides ...
(Date:7/14/2014)... Employers looking to lower their ... more benefit options must understand how purchasing benefits ... are the future of employee benefits. , Horizon ... BCBSNJ) is offering a free webinar, The Future ... Options, to demonstrate how HorizonSelect, its private online ...
(Date:7/14/2014)... Continuing a steady trend of growth in the ... of first-quarter success with Orange Regional Medical Center, Nexus ... by CEO and President Dr. Virginia Feldman – has ... members. Robert Poltenovage has joined the Nexus ... LPN and Angelica D’Amico have joined the Nexus Health ...
(Date:7/14/2014)... The European Lecithin Market report explains ... and projection of revenue. The Lecithin Market in Europe ... 2012 to $315.9 million by 2019, at a CAGR ... the TOC of the European Lecithin Market report, to ... also provides a glimpse of the segmentation in the ...
(Date:7/14/2014)... use of antibiotics is still prevalent among terminal patients ... despite little evidence that the medications improve symptoms or ... effects. , The use of antibiotics is so engrained ... discharged from hospitals directly to a hospice program leave ... one fourth of them don,t have a documented infection ...
Breaking Medicine News(10 mins):Health News:The North America Biostimulant Market is Expected to Reach $490.1 Million by 2018 - New Report by MicroMarket Monitor 2Health News:The North America Biostimulant Market is Expected to Reach $490.1 Million by 2018 - New Report by MicroMarket Monitor 3Health News:No Cost Employer Webinar to Demonstrate How Private Exchanges Can Lower Benefit Costs While Increasing Options for Employees 2Health News:Nexus Health Resources Continues Growth, Outstanding Health Care Coordination With Addition of Three New Team Members 2Health News:The Lecithin Market in Europe is Expected to Reach $315.9 Million by 2019 - New Report by MicroMarket Monitor 2Health News:The Lecithin Market in Europe is Expected to Reach $315.9 Million by 2019 - New Report by MicroMarket Monitor 3Health News:Antibiotic use prevalent in hospice patients despite limited evidence of its value 2
... , TAMPA, Fla. , Jan. ... the United States Preventative Task Force (USPTF), the Obesity Action ... add health insurance coverage of the recommended childhood obesity treatments. ... treating childhood obesity in moderate to intensive programs helps children ...
... , MORRISTOWN, N.J. , Jan. 19 ... a leading specialty pharmaceutical company, today confirmed that its subsidiary, ... (ANDA) with the U.S. Food and Drug Administration (FDA) seeking ... the expiration of U.S. Patent No. 5,827,529.  Watson,s lidocaine topical ...
... , Berk Prepares to Return as CEO , ... President Joel Seligman today announced that on March 1 ... full-time CEO of the Medical Center while Mark B. Taubman ... of Rochester School of Medicine and Dentistry .   , "I am excited ...
... will be held in Barcelona, Spain (Centre Convencions Internacional ... 24 - Saturday 27 March 2010. The ... the only one that involves all the major players ... between clinicians, scientists and patients in a partnership of ...
... survivors wait up to five years before disclosing they were ... Montral, the Universit du Qubec Montral and the Universit ... . "The number of victims who never reveal their ... very high," says co-author Mireille Cyr, a psychology professor of ...
... closely supported by a nurse-physician primary care team are twice ... those who receive usual care, according to a study by ... The research, published online in the latest edition of the ... 18 months of a randomized controlled trial, Guided Care recipients ...
Cached Medicine News:Health News:Obesity Action Coalition Calls on Insurers and Employers to Increase Access to Childhood Obesity Treatments Based on Recent United States Preventative Task Force Recommendations 2Health News:Watson Confirms Filing of FDA Application for Generic Lidoderm(R) 2Health News:Watson Confirms Filing of FDA Application for Generic Lidoderm(R) 3Health News:New Dean of School of Medicine and Dentistry Announced 2Health News:New Dean of School of Medicine and Dentistry Announced 3Health News:Disclosing sexual abuse is critical 2Health News:Guided Care participants rate quality of health care high 2
Disposable Feather Blades, 50 per pack...
Knife sharpening back for Standard Knife, C Profile...
... The Cryostage freezing stage is a refrigerated design ... holder, primarily for use with the 8000 sledge ... sledge microtomes. ,The refrigerated stage gives a large ... surface is ridged to provide good adhesion between ...
... necessary to cool a specimen below room temperature. ... most microtomes and will permit specimen cooling from ... The equipment consists of a cooling stage and ... suited for operation with a base sledge microtome, ...
Medicine Products: